CXS 4001
Latest Information Update: 20 Jul 2007
At a glance
- Originator ChemGenex Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 21 Jun 2004 AGT Biosciences has merged with ChemGenex Therapeutics Inc to form ChemGenex Pharmaceuticals
- 15 Apr 2002 Preclinical trials in Solid tumours in USA (unspecified route)